Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences GAAP product gross margin by Quarter
GAAP product gross margin (%) (%)
Gilead Sciences GAAP product gross margin: 79.3% in Q2 2026, up 0.6 pts from a year earlier.
Latest, Q2 2026
79.3%
Period ended Jun 30, 2026
Change on a year earlier
+0.6 pts
78.7% in Q2 2025
History
39 quarters
Since Q4 2016
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
“|| GAAP product gross margin | 79.3 | % | 78.7 | % | 79.3 | % | 77.7 | %”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K & Form 8-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences GAAP product gross margin (%), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gaap-gross-margin-pct
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.